CNTB (Connect Biopharma Holdings) Research & Development: $46.20 Mil (TTM As of Mar. 2026)


CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.13
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings Research & Development?

Connect Biopharma Holdings CNTB +1.44% 7 Research & Development is $46.20 Mil as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Connect Biopharma Holdings's Research & Development for the three months ended in Mar. 2026 was $15.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $46.20 Mil.

Connect Biopharma Holdings  (NAS:CNTB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Connect Biopharma Holdings Research & Development Related Terms

Connect Biopharma Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Connect Biopharma Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings Research & Development Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 80.50 96.63 53.00 29.26 37.80

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.63 8.77 11.11 11.28 15.03
CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Connect Biopharma Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $46.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $46.20 Mil mean?
Connect Biopharma Holdings (CNTB) has a Research & Development of $46.20 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Connect Biopharma Holdings and its competitors.
Is Connect Biopharma Holdings' Research & Development too high?
Connect Biopharma Holdings' current Research & Development is $46.20 Mil. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Research & Development compare to ANTX and VXRT?
Connect Biopharma Holdings' Research & Development of $46.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Connect Biopharma Holdings and its competitors. Connect Biopharma Holdings's current Research & Development is $46.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Research & Development of $46.20 Mil. The current Research & Development is $46.20 Mil. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Research & Development is $46.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price